Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Inhibitors to factor VIII (FVIII) or IX (FIX) in patients with haemophilia A or B create a challenging problem for the treatment of these patients. Recombinant FVIIa (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) is a realistic treatment option, owing to its specific mode of action and lack of immunogenicity. This was a multicentre, open-label, compassionate-use trial in patients with severe haemophilia A (FVIII:C < 1%) or B (FIX:C < 1%) with inhibitors, acquired antibodies to FVIII or FIX, or FVII deficiency (FVII:C < 5%), for whom alternative therapies had failed or were contraindicated. Patients received rFVIIa treatment for life- or limb-threatening bleeding episodes or for coverage during essential surgery. The mean rFVIIa dose was approximately 90 microg kg-1 for haemophilia A/B and acquired inhibitor patients, and 25 microg kg-1 for FVII-deficient patients. Efficacy data for 67 treatment episodes (45 bleeding episodes, 22 surgical procedures) are presented; seven patients were treated for a concurrent serious bleeding episode and surgical procedure. At the end of treatment, rFVIIa was effective or partially effective in 85% of serious bleeding episodes. During surgery, bleeding was assessed as none or less than or equivalent to normal in 91% of surgical procedures; postoperatively, 91% of procedures were associated with no or minimal oozing. During 60 separate treatment episodes, 26 adverse events (22 nonserious, four serious) were reported in 15 patients, during 17 bleeding episodes or surgical procedures. Only 10 were considered as having a possible, probable, or unknown relationship with rFVIIa; of these, fever (n=2) and thrombophlebitis (n=3) were the most common. There was no evidence of disseminated intravascular coagulation. In conclusion, rFVIIa is an effective, well-tolerated treatment for serious bleeding episodes and bleeding associated with surgical procedures in patients with severe haemophilia A/B with inhibitors, acquired inhibitors, or FVII deficiency.
Scharrer
I
I
Klinikum der Johann Wolfgang Goethe-Universität, Zentrum der Inneren Medizin, Frankfurt am Main, Germany.
D000293:Adolescent; D000328:Adult; D000368:Aged; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000276:immunology / Q000627:therapeutic use; D005168:Factor VII Deficiency / Q000188:drug therapy; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use; D015942:Factor VIIa / Q000592:standards / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology; D005858:Germany; D006395:Hemarthrosis / Q000188:drug therapy / Q000209:etiology; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D002836:Hemophilia B / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D007223:Infant; D020300:Intracranial Hemorrhages / Q000188:drug therapy / Q000209:etiology; D019586:Intracranial Hypertension / Q000188:drug therapy / Q000209:etiology; D007518:Isoantibodies / Q000097:blood; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use / Q000633:toxicity; D016896:Treatment Outcome
D007518:Isoantibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX; D015942:Factor VIIa